EC approves Sanofi’s Aubagio for paediatric MS patients
Aubagio has been authorised for the treatment of paediatric patients aged ten to 17 years living with RRMS
Read More
Tag: Aubagio
TG Therapeutics’ ublituximab tops Sanofi’s Aubagio in MS trial
Ublituximab significantly reduced the annualised relapse rate in patients with relapsing forms of multiple sclerosis
Read More
Janssen’s ponesimod holds up against Aubagio in late-stage trial
The drug is a selective sphingosine-1-phosphate receptor 1 (S1P1) modulator.
Read More
- MRM Health collaborates with Oncode Institute and Netherlands Cancer Institute
- Sobi to acquire Arthrosi Therapeutics, strengthening gout treatment pipeline
- Lindus Health and Quotient Sciences announce strategic partnership to accelerate drug development
- Title21 Health Solutions joins the Blood and Cells Advocacy Roster
- NADMED launches $30,000 metabolomics research award
